The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Cohort Consortium, 2012Parkinson’s Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
Objective/Rationale:
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role... -
Rapid Response Innovation Awards, 2012Nigrostriatal Alpha-Synuclein Over-Expression in Young and Aged Pre-Clinical Models
Objective/Rationale:
Accurate pre-clinical models of Parkinson’s disease are needed in order to test novel therapies as well as to further our understanding of the disease itself. The molecule alpha... -
MJFF Research Grant, 2012Generation of Phospho-Ser65 Parkin and Phospho-Thr257 PINK1 Pre-clinical Monoclonal Antibodies and Characterization of Total PINK1 Pre-clinical Monoclonal Antibodies
Objective/Rationale:
Mutations in an enzyme known as PINK1 can cause Parkinson’s disease. There has been
great interest in understanding the function of PINK1 since uncovering the pathways that
PINK1 is... -
MJFF Research Grant, 2012Design of HdAd Type 5 LRRK2 Expression Vectors
Objective/Rationale:
LRRK2 is a gene that is has been implicated in Parkinson’s disease. LRRK2 is a large cDNA of approximately 7.6 kb that precludes it from being expressed in viral vectors such as... -
Therapeutics Development Initiative, 2012Novel Fumarate Esters as Neuroprotective Agents in Parkinson’s Disease
Objective/Rationale:
Fumaric acid esters have shown immuno-modulatory and neuroprotective effects in cell-based systems, pre-clinical models of disease and clinical trials in multiple sclerosis and... -
Clinical Intervention Awards, 2012Sublingually Administered APL-130277 Compared to Apokyn in Healthy Volunteers
Objective/Rationale:
Apomorphine is an under-utilized medication in Parkinson's disease (PD). Despite its strong efficacy as a rescue medication for intermittent "off" episodes in PD and its rapid...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.